Confident CAD management
starts with plaque quantification.
Heartflow Plaque Staging* is
Backed by Evidence.
With outcomes from over 2,800 patients, Heartflow Plaque Staging* is the leading tool for patient risk stratification based on total plaque volume.1
Heartflow Plaque Staging*
Personalizes Individual Cardiac Risk


† Controlling for risk factors, stenosis, and FFRCT.
Built for Action
Medical management recommendations developed by preventive cardiology and CCTA expert consensus are being studied in the DECIDE Registry, the largest prospective registry on plaque analysis.2
Overall considerations: Consider GLP1 treatment if BMI>27 kg/m2 | Lifestyle modifications guidance especially in higher stages.
Stage | Total Plaque Volume | Lipid Biomarkers Thresholds/Goals | Medical Management Currently under clinical evaluation. |
---|---|---|---|
Mild‡ | 1-100 |
|
|
Moderate‡ | >101-250 |
|
|
Severe‡ | >251-750 |
|
|
Extensive | <750 | All as low as can be achieved:
|
|
‡Consider intensifying to next stage if nomogram percentile >50th and/or risk enhancers.3
‡Consider intensifying to next stage if nomogram percentile >50th and/or risk enhancers.3
Measurable Patient Impact
For the first time, modeled outcomes show the risk of CV events could decrease when Heartflow Plaque Staging* guides care.4
18.7mg/dL
Decrease in LDL-C with Plaque Staging* led management
~15%
Suggested decrease in risk of cardiac events based on average LDL-C decrease1